Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab' antibody fragment in de novo renal transplant patients

X
Trial Profile

A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab' antibody fragment in de novo renal transplant patients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FR 104 (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms FIRsT
  • Most Recent Events

    • 05 Jun 2024 According to Veloxis Pharmaceuticals, Inc media release, Pr. Gilles Blancho is principal Investigator of the study.
    • 05 Jun 2024 According to Veloxis Pharmaceuticals, Inc media release, company in collaboration with Nantes University Hospital Present Positive analysis at the American Transplant Congress 2024
    • 30 May 2024 According to Veloxis Pharmaceuticals, Inc media release, Interim analysis data from this trial will be presented at the 2024 American Transplant Congress (ATC). Taking place June 1-5 in Philadelphia, ATC is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top